Comments
Loading...

Rocket Pharmaceuticals Analyst Ratings

RCKTNASDAQ
Logo brought to you by Benzinga Data
$2.70
-0.13-4.59%
At close: -
$2.72
0.020.74%
After Hours: 7:59 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$75.00
Lowest Price Target1
$2.50
Consensus Price Target1
$29.52

Rocket Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:RCKT | Benzinga

Rocket Pharmaceuticals Inc has a consensus price target of $29.52 based on the ratings of 22 analysts. The high is $75 issued by Evercore ISI Group on September 30, 2022. The low is $2.5 issued by Jefferies on May 28, 2025. The 3 most-recent analyst ratings were released by UBS, Canaccord Genuity, and B of A Securities on June 17, 2025, June 3, 2025, and May 28, 2025, respectively. With an average price target of $8.33 between UBS, Canaccord Genuity, and B of A Securities, there's an implied 206.37% upside for Rocket Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Feb
2
1
Mar
1
Apr
9
2
May
2
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

UBS
Canaccord Genuity
B of A Securities
BMO Capital
Scotiabank

1calculated from analyst ratings

Analyst Ratings for Rocket Pharmaceuticals

Buy NowGet Alert
06/17/2025Buy Now83.82%UBS
Colin Bristow40%
$12 → $5MaintainsBuyGet Alert
06/03/2025Buy Now304.41%Canaccord Genuity
Whitney Ijem58%
$34 → $11MaintainsBuyGet Alert
05/28/2025Buy Now230.88%B of A Securities
Jason Zemansky77%
$32 → $9MaintainsBuyGet Alert
05/28/2025Buy Now194.12%BMO Capital
Kostas Biliouris33%
$30 → $8MaintainsOutperformGet Alert
05/28/2025Buy Now598.53%Scotiabank
Greg Harrison47%
$51 → $19MaintainsSector OutperformGet Alert
05/28/2025Buy Now194.12%Leerink Partners
Mani Foroohar50%
$37 → $8DowngradeOutperform → Market PerformGet Alert
05/28/2025Buy Now525%Chardan Capital
Geulah Livshits49%
$46 → $17MaintainsBuyGet Alert
05/28/2025Buy Now-8.09%Jefferies
Andrew Tsai30%
$29 → $2.5DowngradeBuy → HoldGet Alert
05/27/2025Buy Now1444.12%Needham
Gil Blum51%
$42 → $42DowngradeBuy → HoldGet Alert
05/16/2025Buy Now1002.94%Cantor Fitzgerald
Josh Schimmer56%
$20 → $30MaintainsOverweightGet Alert
05/16/2025Buy Now1076.47%Wedbush
Yun Zhong38%
$32 → $32ReiteratesOutperform → OutperformGet Alert
05/16/2025Buy Now1591.18%Chardan Capital
Geulah Livshits49%
$45 → $46MaintainsBuyGet Alert
05/12/2025Buy Now1775%Scotiabank
Greg Harrison47%
$52 → $51MaintainsSector OutperformGet Alert
05/12/2025Buy Now1150%Canaccord Genuity
Whitney Ijem58%
$36 → $34MaintainsBuyGet Alert
05/09/2025Buy Now1554.41%Chardan Capital
Geulah Livshits49%
$54 → $45MaintainsBuyGet Alert
05/09/2025Buy Now1517.65%JP Morgan
Eric Joseph43%
$45 → $44MaintainsOverweightGet Alert
05/09/2025Buy Now377.94%Goldman Sachs
Richard Law46%
$15 → $13MaintainsNeutralGet Alert
04/09/2025Buy Now1444.12%Needham
Gil Blum51%
$42 → $42ReiteratesBuy → BuyGet Alert
03/12/2025Buy Now1738.24%BMO Capital
Kostas Biliouris33%
→ $50Initiates → OutperformGet Alert
03/03/2025Buy Now1811.76%Scotiabank
Greg Harrison47%
$51 → $52MaintainsSector OutperformGet Alert
03/03/2025Buy Now451.47%Goldman Sachs
Richard Law46%
$29 → $15MaintainsNeutralGet Alert
03/03/2025Buy Now1223.53%Canaccord Genuity
Whitney Ijem58%
$39 → $36MaintainsBuyGet Alert
02/28/2025Buy Now1885.29%Chardan Capital
Geulah Livshits49%
$62 → $54MaintainsBuyGet Alert
02/28/2025Buy Now1444.12%Needham
Gil Blum51%
$52 → $42MaintainsBuyGet Alert
12/18/2024Buy Now966.18%Jefferies
Andrew Tsai30%
→ $29Initiates → BuyGet Alert
11/19/2024Buy Now1333.82%Canaccord Genuity
Whitney Ijem58%
$39 → $39MaintainsBuyGet Alert
11/19/2024Buy Now1517.65%Leerink Partners
Mani Foroohar50%
$46 → $44MaintainsOutperformGet Alert
11/19/2024Buy Now2289.71%Cantor Fitzgerald
Josh Schimmer56%
$65 → $65ReiteratesOverweight → OverweightGet Alert
11/19/2024Buy Now1811.76%Needham
Gil Blum51%
$52 → $52ReiteratesBuy → BuyGet Alert
11/18/2024Buy Now2179.41%Chardan Capital
Geulah Livshits49%
$62 → $62MaintainsBuyGet Alert
11/11/2024Buy Now2179.41%Chardan Capital
Geulah Livshits49%
$62 → $62MaintainsBuyGet Alert
11/08/2024Buy Now1811.76%Needham
Gil Blum51%
$52 → $52ReiteratesBuy → BuyGet Alert
10/16/2024Buy Now1738.24%Scotiabank
Greg Harrison47%
→ $50Initiates → Sector OutperformGet Alert
09/30/2024Buy Now1297.06%Canaccord Genuity
Whitney Ijem58%
$38 → $38MaintainsBuyGet Alert
09/17/2024Buy Now1811.76%Needham
Gil Blum51%
$52 → $52ReiteratesBuy → BuyGet Alert
08/06/2024Buy Now1885.29%JP Morgan
Eric Joseph43%
$50 → $54MaintainsOverweightGet Alert
08/06/2024Buy Now2289.71%Cantor Fitzgerald
Josh Schimmer56%
$65 → $65ReiteratesOverweight → OverweightGet Alert
08/06/2024Buy Now2179.41%Chardan Capital
Geulah Livshits49%
$62 → $62MaintainsBuyGet Alert
08/06/2024Buy Now1811.76%Needham
Gil Blum51%
$52 → $52ReiteratesBuy → BuyGet Alert
07/03/2024Buy Now1370.59%Canaccord Genuity
Whitney Ijem58%
$49 → $40MaintainsBuyGet Alert
06/28/2024Buy Now2179.41%Chardan Capital
Geulah Livshits49%
$62 → $62MaintainsBuyGet Alert
06/28/2024Buy Now1811.76%Needham
Gil Blum51%
$53 → $52MaintainsBuyGet Alert
05/07/2024Buy Now1848.53%Needham
Gil Blum51%
$53 → $53ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now1848.53%Needham
Gil Blum51%
$53 → $53ReiteratesBuy → BuyGet Alert
04/02/2024Buy Now1333.82%Goldman Sachs
Richard Law46%
→ $39Initiates → NeutralGet Alert
03/01/2024Buy Now1885.29%UBS
Colin Bristow40%
$56 → $54MaintainsBuyGet Alert
02/27/2024Buy Now1738.24%JP Morgan
Eric Joseph43%
$55 → $50MaintainsOverweightGet Alert
02/27/2024Buy Now2289.71%Cantor Fitzgerald
Josh Schimmer56%
$65 → $65MaintainsOverweightGet Alert
02/13/2024Buy Now1848.53%Needham
Gil Blum51%
$53 → $53ReiteratesBuy → BuyGet Alert
01/31/2024Buy Now2289.71%Cantor Fitzgerald
Louise Chen56%
$65 → $65ReiteratesOverweight → OverweightGet Alert
11/07/2023Buy Now1848.53%Needham
Gil Blum51%
→ $53ReiteratesBuy → BuyGet Alert
10/24/2023Buy Now2289.71%Cantor Fitzgerald
Josh Schimmer56%
→ $65Initiates → OverweightGet Alert
09/13/2023Buy Now1664.71%Stifel
Dae Gon Ha49%
→ $48ReiteratesBuy → BuyGet Alert
09/13/2023Buy Now1848.53%Needham
Gil Blum51%
$60 → $53MaintainsBuyGet Alert
08/11/2023Buy Now1627.94%Canaccord Genuity
Whitney Ijem58%
$49 → $47MaintainsBuyGet Alert
08/11/2023Buy Now2142.65%Chardan Capital
Geulah Livshits49%
→ $61ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now2105.88%Needham
Gil Blum51%
→ $60ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now1664.71%Stifel
Dae Gon Ha49%
$53 → $48MaintainsBuyGet Alert
05/23/2023Buy Now2105.88%Needham
Gil Blum51%
→ $60ReiteratesBuy → BuyGet Alert
05/08/2023Buy Now2142.65%Chardan Capital
Geulah Livshits49%
$63 → $61MaintainsBuyGet Alert
05/05/2023Buy Now1186.76%Raymond James
Steven Seedhouse57%
$33 → $35MaintainsOutperformGet Alert
05/05/2023Buy Now2105.88%Needham
Gil Blum51%
→ $60Reiterates → BuyGet Alert
04/19/2023Buy Now2105.88%Needham
Gil Blum51%
→ $60Reiterates → BuyGet Alert
03/01/2023Buy Now2216.18%Chardan Capital
Geulah Livshits49%
$65 → $63Reiterates → BuyGet Alert
02/28/2023Buy Now2105.88%Needham
Gil Blum51%
→ $60Reiterates → BuyGet Alert
02/01/2023Buy Now1554.41%Morgan Stanley
Michael Ulz65%
→ $45Initiates → OverweightGet Alert
01/23/2023Buy Now1701.47%SVB Leerink
Mani Foroohar50%
$50 → $49MaintainsOutperformGet Alert
12/23/2022Buy Now1186.76%B of A Securities
Greg Harrison47%
$38 → $35MaintainsBuyGet Alert
12/22/2022Buy Now1738.24%SVB Leerink
Mani Foroohar50%
$54 → $50MaintainsOutperformGet Alert
12/06/2022Buy Now1885.29%SVB Leerink
Mani Foroohar50%
$56 → $54MaintainsOutperformGet Alert
11/08/2022Buy Now1848.53%Canaccord Genuity
Whitney Ijem58%
→ $53Initiates → BuyGet Alert
11/07/2022Buy Now1113.24%Raymond James
Steven Seedhouse57%
$34 → $33MaintainsOutperformGet Alert
11/04/2022Buy Now2105.88%Needham
Gil Blum51%
$62 → $60MaintainsBuyGet Alert
11/01/2022Buy Now1186.76%BTIG
Yun Zhong38%
→ $35Initiates → BuyGet Alert
10/03/2022Buy Now2289.71%Chardan Capital
Geulah Livshits49%
$62 → $65MaintainsBuyGet Alert
10/03/2022Buy Now1150%Raymond James
Steven Seedhouse57%
$24 → $34MaintainsOutperformGet Alert
09/30/2022Buy Now2105.88%SVB Leerink
Mani Foroohar50%
$65 → $60MaintainsOutperformGet Alert
09/30/2022Buy Now2657.35%Evercore ISI Group
Joshua Schimmer45%
$65 → $75MaintainsOutperformGet Alert
09/27/2022Buy Now2179.41%UBS
Colin Bristow40%
$68 → $62MaintainsBuyGet Alert
08/09/2022Buy Now782.35%Raymond James
Steven Seedhouse57%
$22 → $24MaintainsOutperformGet Alert
07/26/2022Buy Now1958.82%Stifel
Dae Gon Ha49%
$67 → $56MaintainsBuyGet Alert
07/08/2022Buy Now708.82%Raymond James
Timur Ivannikov37%
→ $22Initiates → OutperformGet Alert
07/06/2022Buy Now2252.94%SVB Leerink
Mani Foroohar50%
$66 → $64MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Rocket Pharmaceuticals (RCKT) stock?

A

The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by UBS on June 17, 2025. The analyst firm set a price target for $5.00 expecting RCKT to rise to within 12 months (a possible 83.82% upside). 42 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Rocket Pharmaceuticals (RCKT)?

A

The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by UBS, and Rocket Pharmaceuticals maintained their buy rating.

Q

When was the last upgrade for Rocket Pharmaceuticals (RCKT)?

A

There is no last upgrade for Rocket Pharmaceuticals

Q

When was the last downgrade for Rocket Pharmaceuticals (RCKT)?

A

The last downgrade for Rocket Pharmaceuticals Inc happened on May 28, 2025 when Leerink Partners changed their price target from $37 to $8 for Rocket Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Rocket Pharmaceuticals (RCKT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on June 17, 2025 so you should expect the next rating to be made available sometime around June 17, 2026.

Q

Is the Analyst Rating Rocket Pharmaceuticals (RCKT) correct?

A

While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a maintained with a price target of $12.00 to $5.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $2.72, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch